Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionPacer Advisors, Inc.
Latest Disclosed Ownership2,284,517 shares
Latest Disclosed Value $ 4,169,402
Pacer Advisors, Inc. reports 30.59% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 6, 2026 - Pacer Advisors, Inc. filed a 13F-HR form disclosing ownership of 2,284,517 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $652,686,507 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on February 24, 2026 disclosing 1,749,366 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 30.59% during the quarter. The current value of the position is $575,241,381 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-06 2026-03-31 13F Nasdaq Common Stock - Domestic 002043423 2,284,517 535,151 30.59 4,169 172.48 0.0107
2026-02-24 2025-12-31 13F/A-1 Sigma Foods SAB de CV Common Stock - Foreign 002043423 1,749,366 690,841 65.26 1,530 80.21 0.0039
2026-02-24 2025-12-31 13F/A-1 Alnylam Pharmaceuticals Common Stock - Domestic 02043Q107 9,588 -1,048,937 3,813 0.0097
2026-02-04 2025-12-31 13F Norfolk Southern Common Stock - Domestic 002043423 1,767,646 709,121 6,808 0.0174
2025-10-15 2025-09-30 13F Alfa SAB de CV Common Stock - Foreign 002043423 1,058,525 63,409 6.37 849 15.67 0.0021
2025-08-12 2025-06-30 13F Alfa SAB de CV Common Stock - Foreign 002043423 995,116 995,116 734 0.0018
2024-11-12 2024-09-30 13F Alnylam Pharmaceuticals Common Stock - Domestic 02043Q107 0 -461 -100.00 0 -100.00
2024-08-13 2024-06-30 13F Alnylam Pharmaceuticals Common Stock - Domestic 02043Q107 461 176 61.75 112 166.67 0.0003
2024-05-10 2024-03-31 13F Alnylam Pharmaceuticals Common Stock - Domestic 02043Q107 285 285 43 0.0001
2021-07-21 2021-06-30 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 0 -550 -100.00 0 -100.00
2021-04-05 2021-03-31 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 550 -472 -46.18 78 -41.35 0.0014
2021-01-20 2020-12-31 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 1,022 184 21.96 133 9.02 0.0025
2020-10-19 2020-09-30 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 838 838 122 0.0026
2019-02-13 2018-12-31 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 0 -2,640 -100.00 0 -100.00
2018-11-14 2018-09-30 13F ALNYLAM PHARMACEUTICALS Common Stock 02043Q107 2,640 2,640 231 0.0087
2018-05-14 2018-03-31 13F Alnylam Pharmaceuticals Com 02043Q107 0 -1,525 -100.00 0 -100.00
2018-02-14 2017-12-31 13F Alnylam Pharmaceuticals Com 02043Q107 1,525 -10,241 -87.04 194 -85.96 0.0136
2017-11-08 2017-09-30 13F Alnylam Pharmaceuticals Com 02043Q107 11,766 156 1.34 1,382 49.24 0.1225
2017-08-08 2017-06-30 13F ALNYLAM PHARMACEUTICALS Com 02043Q107 11,610 2,093 21.99 926 89.75 0.0916
2017-05-09 2017-03-31 13F ALNYLAM PHARMACEUTICALS Com 02043Q107 9,517 1,544 19.37 488 63.21 0.0598
2017-02-08 2016-12-31 13F ALNYLAM PHARMACEUTICALS Com 02043Q107 7,973 386 5.09 299 -41.83 0.0426
2016-11-10 2016-09-30 13F ALNYLAM PHARMACEUTICALS Com 02043Q107 7,587 657 9.48 514 33.51 0.0781
2016-08-12 2016-06-30 13F ALNYLAM PHARMACEUTICALS Com 02043Q107 6,930 5,790 507.89 385 434.72 0.0608
2016-05-13 2016-03-31 13F ALNYLAM PHARMACEUTICALS Com 02043Q107 1,140 55 5.07 72 -29.41 0.0163
2016-02-17 2015-12-31 13F ALNYLAM PHARMACEUTICALS Com 02043Q107 1,085 1,085 102 0.0240
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.